Last Update 06 Apr 26

OMDA: Q4 Outperformance And 2026 Guidance Conservatism Are Expected To Drive Upside

The updated analyst price target for Omda now reflects a more cautious tone seen across recent NOK-based targets, as analysts factor in refreshed models following Q4 results, revised guidance and ongoing debate around how conservative the medium-term outlook might be.

Analyst Commentary

Street research on Omda clusters around lowered price targets in the near term, but most firms are maintaining positive or neutral ratings, pointing to a mix of execution momentum and valuation questions. Recent Q4 results, refreshed guidance and new coverage are giving investors more data to weigh around growth, profitability and how conservative the medium term outlook might be.

Bullish Takeaways

Bullish analysts highlight that Q4 results included an 8% revenue beat and a $7m EBITDA beat, which they see as evidence that Omda is executing ahead of prior expectations, even as official guidance stays cautious.
Several bullish analysts point to continued momentum across all programs and multi condition adoption, including benefits from GLP 1 usage, as supportive of Omda's longer term growth potential despite pressure on the broader Healthcare Information Technology space.
Some firms that cut their targets describe Omda's outlook as including pockets of conservatism, which they view as allowing room for upside if management delivers against current plans.
One major bank cites a return to more normalized patterns where organic growth defines relative valuation. For bullish analysts, this suggests Omda's underlying business trends are more important than recent share price moves.

Bearish Takeaways

Bearish analysts, or those taking a more cautious stance, are almost uniformly revising price targets lower, which signals reduced upside expectations even where ratings remain Buy, Outperform or Overweight.
Some commentary flags Omda's client concentration and ownership structure as factors that complicate competitive dynamics, which can cap how much risk certain investors may be willing to take at current valuation levels.
One neutral initiation with an Equal Weight rating and a US$17 target frames the setup as a balanced risk and reward. For more cautious analysts, this implies that recent growth in cardiometabolic programs is offset by structural and competitive uncertainties.
Across the coverage, valuation pressure on Healthcare Information Technology is an ongoing theme, and even bullish analysts acknowledge that this sector backdrop is a headwind for multiple expansion in the near term.

What's in the News

Omda AS reiterated earnings guidance for 2026, with revenue expected in the range of NOK 500 million to NOK 525 million, indicating no change to the existing medium-term outlook (Corporate Guidance).

Valuation Changes

Fair Value: NOK 57.0 per share is unchanged, indicating no adjustment to the modelled intrinsic value.
Discount Rate: The discount rate has fallen slightly from 9.32% to 9.18%, a small reduction in the required return used in the valuation.
Revenue Growth: Forecast revenue growth remains steady at 4.77% a year, with no change in the underlying top line expectation.
Net Profit Margin: Projected net profit margin is stable at 7.72%, implying no adjustment to expected profitability levels.
Future P/E: The forward P/E multiple is marginally lower, moving from 33.85x to 33.72x, a very modest compression in the valuation multiple applied to earnings.

1 view

Key Takeaways

High reliance on public sector and Nordic-European contracts exposes Omda to risks from budget constraints, regulatory changes, and potential cuts in IT spending.
Sustained competitiveness demands heavy investment in R&D and cyber compliance, which could hinder margin growth amid intensifying international competition.
Strong recurring revenue, robust customer retention, digital health expansion, and strategic cost and M&A initiatives are driving Omda's sustainable growth and margin improvement.

Catalysts

About Omda

Provides software solutions for the healthcare and emergency response sector in Norway, Sweden, Denmark, Finland, and internationally.What are the underlying business or industry changes driving this perspective?

Investors may be overestimating Omda's ability to maintain strong revenue growth rates, as much of its expansion relies on ongoing digitization in healthcare and public investment, which can be challenged by potential macroeconomic pressures or austerity measures-raising the risk of future revenue disappointments if public sector IT spending slows.
The company's heavy dependence on publicly funded, Nordic and European contracts creates long-term exposure to regulatory tightening and cyclically constrained government budgets, suggesting margins and recurring revenues could be impacted by compliance cost increases or contract cutbacks.
Although the company highlights strong, resilient recurring revenues and successful margin expansion, the required pace of R&D and platform upgrades to remain competitive (including integration of AI and data analytics) may keep operating expenses higher for longer, compressing net margins over time.
Market valuations may not fully account for Omda's vulnerability to increasing data privacy regulation complexity and the continually evolving cyber-threat landscape, both of which carry the potential for higher costs, reputational risks, and lower profitability in the future.
Despite positive outlooks regarding geographic and product expansion, Omda faces intensifying competition from large established international health tech firms and startups; this could erode its pricing power and market share, placing future revenue and earnings growth at risk if growth expectations are priced for near-perfection.

Omda Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Omda's revenue will grow by 4.8% annually over the next 3 years.
Analysts assume that profit margins will increase from 1.3% today to 7.7% in 3 years time.
Analysts expect earnings to reach NOK 44.0 million (and earnings per share of NOK 2.08) by about April 2029, up from NOK 6.6 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 34.6x on those 2029 earnings, down from 124.1x today. This future PE is lower than the current PE for the NO Healthcare Services industry at 70.4x.
Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
To value all of this in today's terms, we will use a discount rate of 9.18%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The aging global population and increasing demand for efficient, digitalized healthcare solutions are likely to drive sustained volume growth for Omda, as evidenced by their expanding footprint in specialized sectors (e.g., Emergency and fertility areas), supporting long-term revenue stability and growth.
The company's highly diversified revenue base-over 750 active contracts across 26 countries, with >79% recurring revenues and ultra-low churn (<2%)-demonstrates strong customer retention, resilience, and predictability, countering risks of revenue decline.
Ongoing digital transformation in healthcare, including adoption of patient-centric IT platforms and integration of AI-driven modules, positions Omda well to capture both organic growth (guided at 5–10% per year) and higher-margin value-added sales, enhancing future gross margins and earnings.
Strategic cost efficiencies (such as COGS reduction toward 5%, selective FTE reductions, and productivity gains via AI-assisted development) have led to significant EBITDA margin improvement (from 12% to 20% YoY, aiming for 28%–32% in 2026), supporting robust future net margin and earnings expansion.
Prudent, disciplined M&A activity-focused on acquiring complementary software and domain expertise within existing verticals-and the ability to leverage favorable market conditions for acquisitions (lower upfront cash, earnouts) suggest further scalable inorganic growth, diversification, and upside for both revenue and margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of NOK57.0 for Omda based on their expectations of its future earnings growth, profit margins and other risk factors.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be NOK570.0 million, earnings will come to NOK44.0 million, and it would be trading on a PE ratio of 34.6x, assuming you use a discount rate of 9.2%.
Given the current share price of NOK40.0, the analyst price target of NOK57.0 is 29.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Omda?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Healthcare Digitization Will Spark Competitive Gains Amid Regulatory Pressures